Measurement of AMPA receptor density in patients with ASD: a PET study

Not Applicable

• Conditions: Autism spectrum disorder

• Registration Number: JPRN-UMIN000039355
• Lead Sponsor: Department of Physiology,Yokohama City University, School of Medicie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-01
• Study Completion: 2023-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

(1) being pregnant or breast-feeding, or wishing to become pregnant, (2) being sensitive to alcohol, (3) comorbidity of serious neurological illness, (4) history of epilepsy, (5) use of perampanel or topiramate within 4 weeks, (6) history of substance use disorder for the past 6 months, (7) positive result on urine screening of substances that cause dependence, (8) having a metal object or pace maker in the body, (9) inappropriate size of head, neck, or body for MRI scan, (10) having large tatoo, (11) suffering from serious claustrophobia, (12) presence of significant brain anomaly, (13) abnormal lab results as follows: serum creatinine level of >=1.5, AST of >=150, or ALT of >=150, (14) having participated in any clinical trial that included the use of unapproved nuclear test within 6 months, (15) having participated in any other clinical trial that included intervention, (16) being judged to be inappropriate for participation by a study medical doctor, (17) IQ of <70 on the WAIS-III

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AMPA receptor density in right middle frontal gyrus and left superior frontal gyrus and CSS score in the ADOS-2

Secondary Outcome Measures

Name	Time	Method
AMPA receptor density and scores in the following scales:Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), Autism-Spectrum Quotient (AQ), Post-traumatic Stress Diagnostic Scale (PDS), Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS),Y-BOCS,WAIS-3 Adverse events during 7 days after administration of [11C]K-2